ADAMTS13 recovery in caplacizumab-treated TTP

被引：0
|
作者：
Laemmle, Bernhard [1 ,2 ]
机构：
[1] Univ Bern, Bern, Switzerland
[2] Univ Med Ctr Mainz, Mainz, Germany
来源：
BLOOD | 2024年 / 143卷 / 18期
关键词：
D O I：
10.1182/blood.2024023862
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1785 / 1786
页数：2
相关论文
共 50 条
  • [31] ADAMTS13 Overtesting in Hospitalized Patients with Suspected TTP: A Retrospective Study
    Ananthaneni, Anil
    Grewal, Udhayvir Singh
    Brown, Tyiesha Sharron
    Al-Yafeai, Zaki
    Master, Samip R.
    Beedupalli, Kavitha
    BLOOD, 2022, 140 : 5019 - 5020
  • [32] Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor
    Schleinitz, N.
    Ebbo, M.
    Mazodier, K.
    Poullin, P.
    Bernit, E.
    Veit, V.
    Veyradier, A.
    Fakhouri, F.
    Kaplanski, G.
    Harle, J.-R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) : 417 - 418
  • [33] Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond
    Favaloro, Emmanuel J.
    Pasalic, Leonardo
    Henry, Brandon
    Lippi, Giuseppe
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : 1049 - 1055
  • [34] Utilization Of ADAMTS13 Testing In Suspected Thrombotic Thrombocytopenic Purpura (TTP)
    Lee, Mijung
    Hardin, Colin A.
    Chapman, Bonnie
    Duffy, Steven M.
    Spektor, Zhanna
    Gajra, Ajeet
    BLOOD, 2013, 122 (21)
  • [35] In Vitro Efficacy of Recombinant ADAMTS13 in Acquired TTP Patients with Anti-ADAMTS13 Inhibitory Antibody
    Plaimauer, Barbara
    Juno, Claudia
    Scheiflinger, Friedrich
    BLOOD, 2008, 112 (11) : 800 - 801
  • [36] Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era
    Prasannan, Nithya
    Thomas, Mari
    Stubbs, Matthew
    Westwood, John-Paul
    de Groot, Rens
    Singh, Deepak
    Scully, Marie
    BLOOD, 2023, 141 (18) : 2206 - 2213
  • [37] DETAILED INVESTIGATION OF ADAMTS13 ACTIVITY AND ANTI-ADAMTS13 IGG ANTIBODY LEVELS IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS TREATED WITH CAPLACIZUMAB
    Reti, M.
    Icleanu, A.
    Varkonyi, A.
    Kiraly, A.
    Bogsch, L.
    Farkas, Z.
    Remenyi, P.
    Prohaszka, Z.
    Sinkovits, G.
    HAEMOPHILIA, 2023, 29 : 39 - 40
  • [38] Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy
    Tanaka, Haruyuki
    Sakai, Kazuya
    Tamura, Shusuke
    Shiwaku, Hiroya
    Nakamura, Junko
    Ueda, Yasunori
    Bamba, Seiya
    Nishikubo, Masashi
    Nagai, Yuya
    Matsumoto, Masanori
    ANNALS OF HEMATOLOGY, 2025, : 1507 - 1514
  • [39] Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
    Wu, H.
    VOX SANGUINIS, 2008, 95 : 77 - 77
  • [40] Low ADAMTS13 activity in clinical remission predicts the risk of TTP relapses
    Wu, H. M.
    Cataland, S. R.
    Kennedy, M. S.
    Lin, S.
    Jin, M.
    TRANSFUSION, 2007, 47 (03) : 14A - 14A
12345